|Bid||0.00 x 3200|
|Ask||48.42 x 4000|
|Day's range||46.41 - 47.00|
|52-week range||41.03 - 58.37|
|PE ratio (TTM)||19.13|
|Forward dividend & yield||1.28 (2.76%)|
|1y target est||60.40|
Novo Nordisk A/S said its diabetes treatment Tresiba showed “significantly improved” blood sugar control and lower rates of hypoglycemia compared with insulin glargine U300 in real-world evidence study....
Roche (RHHBY) will buy the remaining stake in Foundation Medicine for $2.4 billion. PTC Therapeutics (PTCT) presents encouraging preliminary data from an early-stage study in spinal muscular atrophy.
Novo Nordisk (NVO) announces positive headline results of two phase III studies PIONEER oral formulation of Ozempic (semaglutide) as a treatment for adults with type II diabetes.
Novo Nordisk (NVO) enters into a research collaboration and option agreement with Kallyope, Inc. to develop novel therapies for diabetes and obesity.
Several big pharma companies are about to lose patent exclusivity for blockbuster drugs. Should investors be worried?
Shares in Novo Nordisk (NOVOb.CO) opened down 4 percent on Friday after a media report citing anonymous sources said the world's biggest diabetes drug company mulls axing up to 3,000 staff and dropping its long-term financial targets. Denmark's Novo Nordisk said in May that the new rules would cut its 2019 sales by 1-2 percent but kept its long-term operating growth forecast of 5 percent. According to Danish daily Borsen, the firm is now considering ditching the long-term target due to "uncertain and unpredictable markets".
In the first quarter, Novartis’s (NVS) revenue grew 10% to ~$12.7 billion from ~$11.5 billion. As we discussed in the previous part, it reported EPS of $1.28, meeting analysts’ estimate. Its revenue of ~$12.7 billion surpassed analysts’ estimate of ~$12.6 billion, marking ~10% YoY (year-over-year) growth.
Novo Nordisk's (NVO) oral formulation of Ozempic acts better in lowering blood sugar levels in adults with type II diabetes than Eli Lilly's Jardiance, in the second phase IIIa study, PIONEER 2.
Obesity is a global epidemic. Nearly one-quarter (22%) of the people in the world will be obese by 2045, up from 14% in 2017, and one in eight will have type 2 diabetes, up from 9% in 2017, it concluded. Using a World Health Organization database and dividing each country’s population into age groups, the authors suggest that — in order to stabilize the rate of global diabetes at 10% — obesity rates must fall from the current level of 14% to 10% by 2045.
AstraZeneca (AZN) is one of the leading pharmaceutical companies that deals with primary care and specialty care products. Though it’s headquartered in London, England, the company reports its revenue in US dollars. The company is set to release its 1Q18 earnings on May 18.
Novartis’s (NVS) EV (enterprise value) is $206.9 billion and its EV-to-revenue ratio is 4.1. The stock is trading at a forward PE (price-to-earnings) ratio of 13.3, and its PEG (price-to-earnings-to-growth) ratio is 2.2. At present, Novartis’ price-to-sales ratio is 3.6, and its price-to-book ratio is 2.4.
In 2018, stock markets, especially in the pharmaceutical sector, have seen heightened volatility. While the S&P 500 has recovered a bit from its fluctuation this year and has fallen only 0.12% year-to-date, the iShares US Pharmaceuticals ETF (IHE), SPDR S&P Pharmaceuticals ETF (XPH), VanEck Vectors Pharmaceutical ETF (PPH), and First Trust NASDAQ Pharmaceuticals ETF (FTXH) have fallen 4.4%, 5.9%, 3.5%, and 2.5%, respectively, indicating that pharma stocks are underperforming the overall market.
Denmark's Novo Nordisk (NOVOb.CO), the world's biggest maker of diabetes drugs, reported first-quarter operating profit above expectations on Wednesday and raised the lower end of its 2018 sales and profit forecast. Operating profit fell 8 percent to 12.4 billion Danish crowns (1.5 billion pounds) in the January to March quarter compared with a year ago, hit by the depreciation of the U.S. dollar, but beat an average 11.8 billion crown forecast in a Reuters poll of analysts. With its traditional insulin treatments in the firing line due to U.S. price pressure, Novo Nordisk is pinning hopes for growth on new obesity drugs and a once-weekly injection and tablet version of its semaglutide drug.
GlaxoSmithKline’s (GSK) Consumer Healthcare business includes various products for oral health, wellness, nutrition, and skin health. The consumer healthcare business reported revenues of ~2.0 billion pounds in 1Q18, a ~3% decrease compared to 1Q17.
GlaxoSmithKline’s (GSK) Pharmaceuticals business includes various Immuno-inflammation products, HIV products, Respiratory products, and Established products. The Pharmaceuticals business segment reported revenues of ~4.0 billion pounds in 1Q18.
In March, Novo Nordisk (NVO) received an exclusive worldwide license for EpiDestiny’s sickle cell disease program, EPI01. Novo Nordisk will pay more than $400 million as an upfront payment to EpiDestiny for the license. EpiDestiny will also receive development and sales milestone payments from Novo Nordisk along with royalties on net sales of the product.
In 4Q17, Novo Nordisk (NVO) generated revenues of 28 billion Danish kroner, which is a ~2% decline on a YoY (year-over-year) basis.